On Monday, July 15, 2024, the European Innovation Council (EIC) executive agency announced the allocation of €411 million in funding to 68 innovative companies as part of the EIC Accelerator project call, which closed in March. Among the selected companies, 13 are based in France, placing the country at the top of the ranking alongside Germany. One of these honored French companies is Apmonia Therapeutics.

Who is Apmonia Therapeutics?

Apmonia Therapeutics is a company founded in 2019 within the MEDyC laboratory (UMR CNRS 7369), a research unit associated with the University of Reims Champagne-Ardenne and the CNRS. It was established with the support of SATT Nord, an organization that helps transform scientific discoveries into tangible products.

The company focuses on developing new medical treatments, particularly for cancer. Their approach targets the extracellular matrix, a network that surrounds and supports cells in our body. Using advanced technologies, Apmonia Therapeutics is working on innovative solutions to better treat cancer patients.

Promising Mixed Funding

The funding awarded by the EIC will combine grants and equity, providing Apmonia Therapeutics with the resources to continue its research and bring its innovations to fruition. This recognition by the EIC highlights the significance of French innovation in the biotechnology and medical research fields and marks a significant step forward in the development of tomorrow’s therapies.

In summary, this selection by the EIC is excellent news for Apmonia Therapeutics and for all those hoping to see new cancer therapies emerge. It also underscores the important role of URCA in the development of innovative solutions and the creation of high-potential start-ups.